DK3826639T3 - Optimeret dosering af diaminophenothiaziner i populationer - Google Patents
Optimeret dosering af diaminophenothiaziner i populationer Download PDFInfo
- Publication number
- DK3826639T3 DK3826639T3 DK19752425.9T DK19752425T DK3826639T3 DK 3826639 T3 DK3826639 T3 DK 3826639T3 DK 19752425 T DK19752425 T DK 19752425T DK 3826639 T3 DK3826639 T3 DK 3826639T3
- Authority
- DK
- Denmark
- Prior art keywords
- diaminophenothiazines
- populations
- optimized dosing
- dosing
- optimized
- Prior art date
Links
- KPYHKEZPEDJERZ-UHFFFAOYSA-N 10h-phenothiazine-1,2-diamine Chemical class C1=CC=C2NC3=C(N)C(N)=CC=C3SC2=C1 KPYHKEZPEDJERZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/29—Mineral substances, e.g. mineral oils or clays
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1812193.9A GB201812193D0 (en) | 2018-07-26 | 2018-07-26 | Optimised dosage of diaminophenothiazines in populations |
| GBGB1909458.0A GB201909458D0 (en) | 2019-07-01 | 2019-07-01 | Optimised dosage of diaminophenothiazines in populations |
| PCT/EP2019/069428 WO2020020751A1 (en) | 2018-07-26 | 2019-07-18 | Optimised dosage of diaminophenothiazines in populations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3826639T3 true DK3826639T3 (da) | 2024-09-23 |
Family
ID=67587720
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK24161602.8T DK4385512T3 (da) | 2018-07-26 | 2019-07-18 | Optimeret dosering af diaminophenothiaziner i populationer |
| DK19752425.9T DK3826639T3 (da) | 2018-07-26 | 2019-07-18 | Optimeret dosering af diaminophenothiaziner i populationer |
| DK24161558.2T DK4364801T3 (da) | 2018-07-26 | 2019-07-18 | Optimeret dosering af diaminophenothiaziner i populationer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK24161602.8T DK4385512T3 (da) | 2018-07-26 | 2019-07-18 | Optimeret dosering af diaminophenothiaziner i populationer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK24161558.2T DK4364801T3 (da) | 2018-07-26 | 2019-07-18 | Optimeret dosering af diaminophenothiaziner i populationer |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US12280061B2 (da) |
| EP (3) | EP4385512B1 (da) |
| JP (2) | JP7465861B2 (da) |
| KR (1) | KR20210038586A (da) |
| CN (1) | CN112805008A (da) |
| AU (2) | AU2019308873B2 (da) |
| BR (1) | BR112021000802A2 (da) |
| CA (1) | CA3106152A1 (da) |
| DK (3) | DK4385512T3 (da) |
| ES (3) | ES3060453T3 (da) |
| FI (3) | FI4385512T3 (da) |
| HR (3) | HRP20260059T1 (da) |
| IL (1) | IL280361B2 (da) |
| MX (2) | MX2021000894A (da) |
| PL (2) | PL3826639T3 (da) |
| PT (3) | PT4364801T (da) |
| SG (1) | SG11202100333XA (da) |
| SI (3) | SI4364801T1 (da) |
| WO (1) | WO2020020751A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101511803B (zh) | 2006-07-11 | 2012-10-31 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
| PT3487505T (pt) | 2016-07-25 | 2023-06-07 | Wista Lab Ltd | Administração e dosagem de diaminofenotiazinas |
| JP7465861B2 (ja) | 2018-07-26 | 2024-04-11 | ウィスタ ラボラトリーズ リミテッド | 集団におけるジアミノフェノチアジンの最適化投与 |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| JP2023525512A (ja) * | 2020-05-05 | 2023-06-16 | ウィスタ ラボラトリーズ リミテッド | Covid-19の治療で使用されるメチルチオニニウム化合物 |
| GB202006659D0 (en) | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| EP4146225B1 (en) * | 2020-05-05 | 2024-10-09 | WisTa Laboratories Ltd. | Methylthioninium compounds for use in the treatment of hypoxemia |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| EP4590275A1 (en) | 2022-09-21 | 2025-07-30 | WisTa Laboratories Ltd. | Novel formulations and vehicles |
| KR20250154422A (ko) | 2023-03-03 | 2025-10-28 | 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 | 미세혈관 뇌질환 치료를 위한 디아미노페노티아진 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| EP1509232B1 (en) | 2002-05-31 | 2008-11-19 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| ES2409683T3 (es) | 2004-09-23 | 2013-06-27 | Wista Laboratories Ltd. | Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT) |
| DK2004155T3 (da) | 2006-03-29 | 2018-04-30 | Wista Lab Ltd | Inhibitorer af protein-aggregation |
| CN104606199B (zh) | 2006-03-29 | 2022-09-13 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 |
| DK2001556T3 (da) | 2006-03-29 | 2014-11-10 | Wista Lab Ltd | Thioninium-forbindelser og anvendelse deraf |
| CN101511803B (zh) | 2006-07-11 | 2012-10-31 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
| PL2167095T3 (pl) | 2007-06-19 | 2019-11-29 | Wista Lab Ltd | Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych |
| DK2205245T3 (da) | 2007-10-03 | 2015-09-28 | Wista Lab Ltd | Terapeutisk anvendelse af diaminophenothiaziner |
| EP2227766A2 (en) | 2007-11-05 | 2010-09-15 | Wista Laboratories Ltd. | Systems for clinical trials |
| WO2010078659A1 (en) | 2009-01-12 | 2010-07-15 | Foster Health Inc. | Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions |
| WO2010104375A1 (en) * | 2009-03-12 | 2010-09-16 | N.V. Nutricia | Stigmasterol for the treatment of alzheimer's disease |
| BR112012006626B8 (pt) | 2009-09-24 | 2021-05-25 | Wista Lab Ltd | processo para a preparação da forma a pentahidratada e método da secagem da forma a pentahidratada de mtc |
| DE102010062810B4 (de) | 2010-09-07 | 2014-03-13 | Immungenetics Ag | 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien |
| CA2827027C (en) | 2011-02-11 | 2019-06-04 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
| DK3258938T3 (da) * | 2015-02-17 | 2021-02-01 | Univ Arizona State | Phenothiazinanaloger som mitokondrie terapeutiske midler |
| PT3487505T (pt) | 2016-07-25 | 2023-06-07 | Wista Lab Ltd | Administração e dosagem de diaminofenotiazinas |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| GB201621817D0 (en) | 2016-12-21 | 2017-02-01 | Wista Lab Ltd | Methods of chemical synthesis |
| JP7465861B2 (ja) | 2018-07-26 | 2024-04-11 | ウィスタ ラボラトリーズ リミテッド | 集団におけるジアミノフェノチアジンの最適化投与 |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
-
2019
- 2019-07-18 JP JP2021502770A patent/JP7465861B2/ja active Active
- 2019-07-18 KR KR1020217005178A patent/KR20210038586A/ko not_active Ceased
- 2019-07-18 CN CN201980061773.1A patent/CN112805008A/zh active Pending
- 2019-07-18 SI SI201931008T patent/SI4364801T1/sl unknown
- 2019-07-18 ES ES24161558T patent/ES3060453T3/es active Active
- 2019-07-18 HR HRP20260059TT patent/HRP20260059T1/hr unknown
- 2019-07-18 ES ES24161602T patent/ES3060455T3/es active Active
- 2019-07-18 EP EP24161602.8A patent/EP4385512B1/en active Active
- 2019-07-18 DK DK24161602.8T patent/DK4385512T3/da active
- 2019-07-18 FI FIEP24161602.8T patent/FI4385512T3/fi active
- 2019-07-18 SG SG11202100333XA patent/SG11202100333XA/en unknown
- 2019-07-18 EP EP19752425.9A patent/EP3826639B1/en active Active
- 2019-07-18 PT PT241615582T patent/PT4364801T/pt unknown
- 2019-07-18 CA CA3106152A patent/CA3106152A1/en active Pending
- 2019-07-18 FI FIEP19752425.9T patent/FI3826639T3/fi active
- 2019-07-18 WO PCT/EP2019/069428 patent/WO2020020751A1/en not_active Ceased
- 2019-07-18 IL IL280361A patent/IL280361B2/en unknown
- 2019-07-18 EP EP24161558.2A patent/EP4364801B1/en active Active
- 2019-07-18 ES ES19752425T patent/ES2989458T3/es active Active
- 2019-07-18 PL PL19752425.9T patent/PL3826639T3/pl unknown
- 2019-07-18 PT PT197524259T patent/PT3826639T/pt unknown
- 2019-07-18 HR HRP20241360TT patent/HRP20241360T1/hr unknown
- 2019-07-18 FI FIEP24161558.2T patent/FI4364801T3/fi active
- 2019-07-18 US US17/262,902 patent/US12280061B2/en active Active
- 2019-07-18 DK DK19752425.9T patent/DK3826639T3/da active
- 2019-07-18 PL PL24161558.2T patent/PL4364801T3/pl unknown
- 2019-07-18 DK DK24161558.2T patent/DK4364801T3/da active
- 2019-07-18 SI SI201931013T patent/SI4385512T1/sl unknown
- 2019-07-18 SI SI201930844T patent/SI3826639T1/sl unknown
- 2019-07-18 HR HRP20251694TT patent/HRP20251694T1/hr unknown
- 2019-07-18 MX MX2021000894A patent/MX2021000894A/es unknown
- 2019-07-18 BR BR112021000802-0A patent/BR112021000802A2/pt unknown
- 2019-07-18 AU AU2019308873A patent/AU2019308873B2/en active Active
- 2019-07-18 PT PT241616028T patent/PT4385512T/pt unknown
-
2021
- 2021-01-22 MX MX2023009856A patent/MX2023009856A/es unknown
-
2022
- 2022-10-07 US US17/961,961 patent/US12263175B2/en active Active
-
2024
- 2024-04-01 JP JP2024058998A patent/JP7763890B2/ja active Active
-
2025
- 2025-02-26 US US19/063,699 patent/US20250302843A1/en active Pending
- 2025-06-17 AU AU2025204524A patent/AU2025204524A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4364801T3 (da) | Optimeret dosering af diaminophenothiaziner i populationer | |
| DK3735147T3 (da) | Rygsæk | |
| PL3886665T3 (pl) | Jednostka dozująca | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| PL3443009T3 (pl) | Przeciwciała i kompozycje anty-tim-3 | |
| PL3653221T3 (pl) | Przeciwciała anty-pvrig i sposoby ich zastosowania | |
| PL3274370T3 (pl) | Przeciwciała anty-ceacam6 i ich zastosowania | |
| SI3350157T1 (sl) | Sestave za doziranje terapevtskih sredstev v celice | |
| DK3193931T3 (da) | Neutralisering af hæmmende veje i lymfocytter | |
| DK3328414T3 (da) | Sammensætning til anvendelse i fremme af sårheling | |
| DK3166911T3 (da) | Inkorporering af biologiske midler i gødning | |
| DK3297653T3 (da) | Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister | |
| DK3350334T3 (da) | Udtryk af rekombinante proteiner i trichoplusia ni pupper | |
| IL269559A (en) | Stable multispecific antibodies | |
| DK3094322T3 (da) | Administration af tasimelteon i fastende tilstand | |
| DK3844162T3 (da) | Hæmmere af alfa-v-beta6-integrin | |
| DK3204767T3 (da) | Proteins anvendelighed i forudsigelsen af in vivo-effekter | |
| EP3137649C0 (en) | METALLIZATION OF SURFACES | |
| DK3247687T3 (da) | Anvendelse af nivelleringsforbindelse | |
| DK3155422T4 (da) | Demaskering af endotoksiner i opløsning | |
| DK3242680T3 (da) | Interleukin-1-receptorantagonist til anvendelse i behandling af cystitis | |
| DK3183359T3 (da) | Effektiv valg af rekombinante proteiner | |
| ES1226030Y (es) | Jarra | |
| EP3844572B1 (fr) | Echappement horloger |